Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets.
March 23, 2015
Blueprint Medicines Appoints Charles A. Rowland, Jr. to its Board of Directors
Download … [Read More...]
March 16, 2015
Blueprint Medicines Publishes Preclinical Proof-of-Concept Data on Promising New Therapy … [Read More...]